MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10792-023-02820-0

Медицинская библиотека · International ophthalmology · 2023

Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.

Isik Puren, Sizmaz Selcuk, Esen Ebru, Uysal Anıl, Demircan Nihal

СтатьяПеревод в очереди

Аннотация

PURPOSE: To compare the visual and anatomic outcomes of intravitreal ranibizumab versus aflibercept in patients with diabetic macular edema (DME) in a real-world study.

METHODS

This is a single-center retrospective comparative study of treatment-naïve patients who received intravitreal ranibizumab or aflibercept administration for DME for at least 12 months on an as needed regimen following three-monthly loading doses. The primary outcomes of the study were the mean change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and central macular volume (CMV). Factors to potentially affect these parameters were also analyzed.

RESULTS

A total of 100 eyes (66 patients) were included in the study. Fifty two eyes received ranibizumab and 48 eyes in aflibercept injections. At the end of follow-up, the improvement in mean BCVA was similar in both groups (p = 0.38). While the decrease in mean CMT at the 4th-month visit was significantly higher in the aflibercept-treated group than in the ranibizumab-treated group (p = 0.02), there was no difference between the two groups at the end of the 1-year follow-up (p = 0.25). There was no significant difference between the two groups in terms of change in mean CMV during the follow-up (p = 0.26, p = 0.27 at 4 and 12 months, respectively). The mean number of injections were also similar between groups (4.5 ± 1 vs. 4.6 ± 1.1 respectively, p = 0.63).

CONCLUSION

In a real-world setting, ranibizumab and aflibercept were both found to be effective in the first-line treatment of DME. Patients with DME who received fewer injections in the real-world could achieve visual and anatomical results comparable to randomized controlled trials participants.

Для цитирования: Isik Puren, Sizmaz Selcuk, Esen Ebru, Uysal Anıl, Demircan Nihal. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.. International ophthalmology. 2023. DOI: 10.1007/s10792-023-02820-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.